ArticleStem cell research & therapy2018
Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.
Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Seizures and blindness onset zone in 7 horses undergoing radiographic myelography in lateral recumbency under inhalation anesthesia.Journal of veterinary internal medicine · 2026Article
- Feasibility and safety of intrathecal transplantation of allogeneic bone marrow mesenchymal stem cells in horses.Veterinary research communications · 2025Article
- Stem Cell Therapy for Diseases of Livestock Animals: An In-Depth Review.Veterinary sciences · 2025Review
- Repeated Intrathecal Stem Cells Optimize Neuroplasticity and Motor Function in Moderate-to-Severe Cerebral Palsy of Rats.Stem cells international · 2025Article
- Fluorescence-Based Mono- and Multimodal Imaging for In Vivo Tracking of Mesenchymal Stem Cells.Biomolecules · 2023Review
- Imaging techniques in veterinary medicineEuropean journal of radiology open · 2023Review
- Preliminary evaluation of safety and migration of immune activated mesenchymal stromal cells administered by subconjunctival injection for equine recurrent uveitis.Frontiers in veterinary science · 2023Article
- Article
- Stem Cell Homing in Intrathecal Applications and Inspirations for Improvement Paths.International journal of molecular sciences · 2022Review
- Ultrasound-guided injections of the equine head and neck: review and expert opinion.Journal of equine science · 2021Review
- [Research progress of hydrogel combined with mesenchymal stem cells in the treatment of spinal cord injury].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2021Review
- Scintigraphic tracking ofStem cell research & therapy · 2021Article
- Biodistribution of Mesenchymal Stromal Cells after Administration in Animal Models and Humans: A Systematic Review.Journal of clinical medicine · 2021Review
- The Usefulness of Mesenchymal Stem Cells beyond the Musculoskeletal System in Horses.Animals : an open access journal from MDPI · 2021Review
- Cutaneous wound healing: canine allogeneic ASC therapy.Stem cell research & therapy · 2020Article
- Review
- Intrathecal Injection in A Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain.International journal of molecular sciences · 2020Article
- Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro.Veterinary ophthalmology · 2020Article
- Safety and Localization of Mesenchymal Stromal Cells Derived from Human Adipose Tissue-Associated Hyaluronic Acid: A Preclinical Study.Stem cells international · 2020Article
- Research Status of Mesenchymal Stem Cells in Liver Transplantation.Cell transplantation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is currently unknown if the intrathecal administration of a high dose of allogeneic mesenchymal stem cells (MSCs) is safe, how MSCs migrate throughout the vertebral canal after intrathecal administration, and whether MSCs are able to home to a site of injury. The aims of the study were: 1) to evaluate the safety of intrathecal injection of 100 million allogeneic adipose-derived MSCs (ASCs); 2) to assess the distribution of ASCs after atlanto-occipital (AO) and lumbosacral (LS) injection in healthy horses; and 3) to determine if ASCs homed to the site of injury in neurologically diseased horses.
methodsSix healthy horses received 100 × 10
resultsThere were no significant alterations in blood, CSF, or neurological examinations at any point after either AO or LS ASC injections into healthy horses. The radioactive signal could be identified all the way to the lumbar area after AO ASC injection. After LS injection, the signal extended caudally but only a minimal radioactive signal extended further cranially. GFP-labeled ASCs were not present at the site of disease at either 1 or 2 weeks following intrathecal administration.
conclusionsThe intrathecal injection of allogeneic ASCs was safe and easy to perform in horses. The AO administration of ASCs resulted in better distribution within the entire subarachnoid space in healthy horses. ASCs could not be found after 7 or 15 days of injection at the site of injury in horses with CVCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.